Mark Gompels

Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial

Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus

A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema

Rate of response to initial antiretroviral therapy according to level of pre‐existing HIV‐1 drug resistance detected by next‐generation sequencing in the strategic timing of antiretroviral treatment (START) study

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

Definition, aims, and implementation of GA²LEN/HAEi Angioedema Centers of Reference and Excellence

First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The <scp>OPuS</scp>‐2 study

A Cross-Sectional Study on Attitudes to and Understanding of Risk of Acquisition of HIV: Design, Methods and Participant Characteristics

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy

Lower Healthcare Costs Associated with the Use of a Single-Pill ARV Regimen in the UK, 2004–2008